Cargando…

Modulation of GLP-1 Levels by a Genetic Variant That Regulates the Cardiovascular Effects of Intensive Glycemic Control in ACCORD

OBJECTIVE: A genome-wide association study in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial identified two markers (rs57922 and rs9299870) that were significantly associated with cardiovascular mortality during intensive glycemic control and could potentially be used, when com...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shah, Hetal S., Morieri, Mario Luca, Marcovina, Santica M., Sigal, Ronald J., Gerstein, Hertzel C., Wagner, Michael J., Motsinger-Reif, Alison A., Buse, John B., Kraft, Peter, Mychaleckyj, Josyf C., Doria, Alessandro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2018
Materias:	Cardiovascular and Metabolic Risk
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780047/ https://www.ncbi.nlm.nih.gov/pubmed/29183908 http://dx.doi.org/10.2337/dc17-1638

Ejemplares similares

Genetic Tools for Coronary Risk Assessment in Type 2 Diabetes: A Cohort Study From the ACCORD Clinical Trial
por: Morieri, Mario Luca, et al.
Publicado: (2018)

Genetic Predictors of Cardiovascular Mortality During Intensive Glycemic Control in Type 2 Diabetes: Findings From the ACCORD Clinical Trial
por: Shah, Hetal S., et al.
Publicado: (2016)

A Type 2 Diabetes Subtype Responsive to ACCORD Intensive Glycemia Treatment
por: Mariam, Arshiya, et al.
Publicado: (2021)

Outcomes of Combined Cardiovascular Risk Factor Management Strategies in Type 2 Diabetes: The ACCORD Randomized Trial
por: Margolis, Karen L., et al.
Publicado: (2014)

PPARA Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid
por: Morieri, Mario Luca, et al.
Publicado: (2020)

Dysglycemia and a History of Reproductive Risk Factors
por: McDonald, Sarah D., et al.
Publicado: (2008)

Cardiovascular Risk Factors Among Youth With and Without Type 2 Diabetes: Differences and possible mechanisms
por: West, Nancy A., et al.
Publicado: (2009)

Predictors of Dyslipidemia Over Time in Youth With Type 1 Diabetes: For the SEARCH for Diabetes in Youth Study
por: Shah, Amy S., et al.
Publicado: (2017)

Characteristics Associated With Decreased or Increased Mortality Risk From Glycemic Therapy Among Patients With Type 2 Diabetes and High Cardiovascular Risk: Machine Learning Analysis of the ACCORD Trial
por: Basu, Sanjay, et al.
Publicado: (2018)

Effect of SARS-CoV-2 Infection and Infection Severity on Longer-Term Glycemic Control and Weight in People With Type 2 Diabetes
por: Wong, Rachel, et al.
Publicado: (2022)

Glycemic variability and cardiovascular disease in patients with type 2 diabetes
por: Martinez, Marcela, et al.
Publicado: (2021)

Cardiovascular outcomes of type 2 diabetic patients treated with SGLT-2 inhibitors versus GLP-1 receptor agonists in real-life
por: Longato, Enrico, et al.
Publicado: (2020)

Cardiorenal protective effects of canagliflozin in CREDENCE according to glucose lowering
por: Charytan, David M, et al.
Publicado: (2023)

Association Between Achieving Inpatient Glycemic Control and Clinical Outcomes in Hospitalized Patients With COVID-19: A Multicenter, Retrospective Hospital-Based Analysis
por: Klonoff, David C., et al.
Publicado: (2021)

Long-term variability of glycemic markers and risk of all-cause mortality in type 2 diabetes: the Look AHEAD study
por: Kaze, Arnaud D, et al.
Publicado: (2020)

Trends in glycemic, blood pressure, and lipid control in adults with diabetes in Switzerland: the CoLaus|PsyCoLaus Study
por: Alkandari, Abdullah, et al.
Publicado: (2023)

Trimethylamine N-oxide and incident atherosclerotic events in high-risk individuals with diabetes: an ACCORD trial post hoc analysis
por: Cardona, Andrea, et al.
Publicado: (2019)

Egg ingestion in adults with type 2 diabetes: effects on glycemic control, anthropometry, and diet quality—a randomized, controlled, crossover trial
por: Njike, Valentine Y, et al.
Publicado: (2016)

Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program
por: Perreault, Leigh, et al.
Publicado: (2022)

Higher burden of cardiometabolic and socioeconomic risk factors in women with type 2 diabetes: an analysis of the Glycemic Reduction Approaches in Diabetes (GRADE) baseline cohort
por: Gulanski, Barbara I, et al.
Publicado: (2023)

Effect of High-Intensity Interval Training on Glycemic Control in Adults With Type 1 Diabetes and Overweight or Obesity: A Randomized Controlled Trial With Partial Crossover
por: Lee, Angela S., et al.
Publicado: (2020)

Use of an electronic health record to identify prevalent and incident cardiovascular disease in type 2 diabetes according to treatment strategy
por: Korytkowski, Mary T, et al.
Publicado: (2016)

Interplay between worsening kidney function and cardiovascular events in patients with type 2 diabetes: an analysis from the ACCORD trial
por: Ferreira, João Pedro, et al.
Publicado: (2021)

How sweet is your love? Disentangling the role of marital status and quality on average glycemic levels among adults 50 years and older in the English Longitudinal Study of Ageing
por: Ford, Katherine J, et al.
Publicado: (2023)

Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial
por: Dagogo-Jack, Samuel, et al.
Publicado: (2021)

Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study
por: Anjana, Ranjit Mohan, et al.
Publicado: (2020)

Association Between Insulin Resistance and Cardiovascular Disease Risk Varies According to Glucose Tolerance Status: A Nationwide Prospective Cohort Study
por: Wang, Tiange, et al.
Publicado: (2022)

Remnant Cholesterol and Its Visit-to-Visit Variability Predict Cardiovascular Outcomes in Patients With Type 2 Diabetes: Findings From the ACCORD Cohort
por: Fu, Liyao, et al.
Publicado: (2022)

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial
por: Buse, John B., et al.
Publicado: (2020)

A Genetic Locus on Chromosome 2q24 Predicting Peripheral Neuropathy Risk in Type 2 Diabetes: Results From the ACCORD and BARI 2D Studies
por: Tang, Yaling, et al.
Publicado: (2019)

Subclinical Atherosclerosis Is Inversely Associated With Gray Matter Volume in African Americans With Type 2 Diabetes
por: Freedman, Barry I., et al.
Publicado: (2015)

Reversibility of Fenofibrate Therapy–Induced Renal Function Impairment in ACCORD Type 2 Diabetic Participants
por: Mychaleckyj, Josyf C., et al.
Publicado: (2012)

The DIVE/DPV registries: evolution of empagliflozin use in clinical practice in Germany
por: Bramlage, Peter, et al.
Publicado: (2020)

Association between hemoglobin A1c variability and hypoglycemia-related hospitalizations in veterans with diabetes mellitus
por: Zhao, Molly J Y, et al.
Publicado: (2021)

Metabolic Syndrome Predicts New Onset of Chronic Kidney Disease in 5,829 Patients With Type 2 Diabetes: A 5-year prospective analysis of the Hong Kong Diabetes Registry
por: Luk, Andrea O.Y., et al.
Publicado: (2008)

White matter hyperintensity volume in pre-diabetes, diabetes and normoglycemia
por: Grosu, Sergio, et al.
Publicado: (2021)

Genetically Driven Hyperglycemia Increases Risk of Coronary Artery Disease Separately From Type 2 Diabetes
por: Merino, Jordi, et al.
Publicado: (2017)

Influence of age on the prevalence and components of the metabolic syndrome and the association with cardiovascular disease
por: Devers, Marion C, et al.
Publicado: (2016)

The effect of metformin on cardiovascular risk profile in patients without diabetes presenting with acute myocardial infarction: data from the Glycometabolic Intervention as adjunct to Primary Coronary Intervention in ST Elevation Myocardial Infarction (GIPS-III) trial
por: Lexis, Chris P H, et al.
Publicado: (2015)

Improving Adiponectin Levels in Individuals With Diabetes and Obesity: Insights From Look AHEAD
por: Belalcazar, L. Maria, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_i41ak6e0acll1gd4meebo3osmu